drugset / Trial / NCT02419170
Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to study the safety and immune response of people who receive a personalized dendritic cell vaccine with the intention of stimulating the immune system to react to lung cancer cells.
Timeline
- Start
- 2016-07
- Primary completion
- 2019-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Personalized mature dendritic cell vaccine | Vaccine | — | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |